Night_Owl_Biotech
Oct 19, 7:19 PM
The attachments compares
$SNDX analyst consensus revenue estimates, valuation & related multiples to
$ARQT (who received an upgrade from Cantor this AM).
5-year SNDX analyst consensus, unchanged between 8/15/26 & last Monday before announcing the IPF data missed, per Seeking Alpha are down only slightly since issuing the news. Be careful because for all we know analysts are waiting for Q326 results before updating estimates.
SNDX now trades at the lowest multiple of analyst consensus versus all peer commercial-stage oncology focused bio, and most non-oncology except for the likes of
$ARDX &
$ACAD (both are stories for another day).
The attachments provide perspective on the disconnect in SNDX valuation if, and we say if 1,000 times, SNDX analyst estimates are credible. SNDX trades for less than 1/3 the multiples of ARQT.
The point of this post is not to bash ARQT. ARQT likely trades for north of
$4B for a good reason, while SNDX is barely over
$1B.
This is not investment advice
$XBI
